We are monitoring the impact of COVID-19 on Europe Diabetic Neuropathy Market Get in touch with us for detailed analysis Know More
Pulished Date October, 2021
ID: 12230
Share on
Share on

Europe Diabetic Neuropathy Market Research Report – Segmented By Disorder, Treatment, Distribution channel, & Country (UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic & Rest of Europe) - Industry Analysis on Size, Share, Trends, COVID-19 Impact & Growth Forecast | 2021 to 2026

Pulished: October, 2021
ID: 12230
Pages: 100

Europe Diabetic Neuropathy Market Size (2021 to 2026)

The Europe Diabetic Neuropathy Market was worth USD 1.38 billion in 2021 and is estimated to be growing at a CAGR of 8.36%, to reach USD 2.06 billion by 2026.

Diabetic neuropathy is a nervous disorder associated with diabetes mellitus. Neuropathy is seen as a common complication for both type 1 and type 2 diabetes.

The European diabetic neuropathy market is being driven by the rising incidence and prevalence of diabetes and the rising comorbidities associated with diabetes, such as blindness and nerve damage. 

Other significant factors expected to boost the growth of the global diabetic neuropathy market include an increasing geriatric population, sedentary lifestyles, urbanization linked to changes in eating habits, genetic composition, and rising incidence of chronic diseases such as obesity and cardiovascular disease. The thighs, hips, buttocks, and legs are affected by proximal diabetic neuropathy. Because of the persistent pain associated with diabetic neuropathy, daily activities might be tough. For more than 25 years, patients with neuropathy have had the highest prevalence of the condition. As a result, the treatment of diabetes has increased, with huge pharmaceutical companies investing considerably in new diabetic medications.

In the near future, factors such as the rising demand for better neuropathy medications are projected to create several market growth prospects. In addition, many local governments and non-governmental organizations (NGOs) around Europe are launching campaigns to promote awareness about diabetic neuropathy prevention. The National Institute of Neurological Disorders and Stroke, for example, funds neuropathy and related problems research.

However, The high costs associated with neuropathy therapy are projected to limit the global diabetic neuropathy market's expansion. The National Institute of Neurological Disorders and Stroke (NINDS) is investing money in neuropathy research. Governments and a number of non-governmental organizations (NGOs) in many countries are working to raise awareness about diabetic neuropathy prevention and management. However, high clinical trial failure rates and tight government rules for product authorization limit the Europe Diabetic Neuropathy Market.

In terms of pain alleviation, the medications used to treat neuropathic pain have had mixed results. A hurdle to the Diabetic Neuropathy Market is the incorrect diagnosis or therapy selection, as well as side effects and the rising cost of medications for the treatment of diabetic neuropathy. The European study linked neuropathy to diabetes and found that the majority of patients with clinically confirmed diabetes are at high risk of acquiring neuropathy.

This research report on the Europe diabetic neuropathy market has been segmented and sub-segmented into the following categories:

By Disorder:

  • Peripheral Neuropathy
  • Autonomic Neuropathy
  • Proximal Neuropathy
  • Focal Neuropathy

By Treatment:

  • Drugs
    • Analgesic
      • Topical
        • Capsaicin
        • Others
      • Opioid:
        • Morphine
        • Others
      • NSAIDs
        • Ibuprofen
        • Naproxen
        • Others
    • Antidepressants:
      • TCAs
        • Amitriptyline
        • Imipramine
        • Others
      • SNRIs
        • Duloxetine
        • Others
      • SSRIs
        • Citalopram
        • Paroxetine
        • Others
    • Anticonvulsant Drugs
      • Gabapentin
      • Pregabalin
      • Topiramate
      • Others
      • Other Drugs
  • Radiotherapy
    • Transcutaneous Electrical Nerve Stimulation (TENS)
    • Others
    • Physiotherapy

By Distribution Channel:

  • Hospitals
  • Clinics
  • Retail Pharmacy
  • Online Pharmacy

By Country:

  • United Kingdom
  • France
  • Spain
  • Germany
  • Italy
  • Russia
  • Sweden
  • Denmark
  • Switzerland
  • Netherlands and
  • Rest of Europe

The Europe Diabetic Neuropathy Market is predicted to grow at a rapid rate during the forecast period. Europe Pacific is predicted to develop at a 7.7% CAGR. The diabetic neuropathy market in Europe is being driven by rising diabetes prevalence and an increase in the geriatric population suffering from chronic disease. Furthermore, the rising number of diabetic patients in developed nations such as Germany, the UK, Italy, France, and Spain are predicted to propel the EUROPE Diabetic Neuropathy Market. Of all the individuals with diabetes worldwide, more than 60% live in Europe. 

Germany dominated the Diabetic Neuropathy market over the forecast period. However, the market is anticipated to account for a substantial share in the coming years. The rising prevalence of diabetes and the growing geriatric population suffering from chronic disease are pushing the diabetic neuropathy market in the country. In addition, the availability of advanced healthcare infrastructure, increasing healthcare spending, and supportive government policies are fuelling the market growth. 

On the other hand, the UK is likely to witness a major share in the diabetic neuropathy market owing to the growing number of health care awareness programs, hospitals equipped with X-ray machines to treat diabetic neuropathy, and numerous patients. 

KEY MARKET PLAYERS:

Johnson & Johnson (Janssen Global Services, LLC), Boehringer Ingelheim GmbH, NeuroMetrix, Inc., Eli Lilly and Company, GlaxoSmithKline plc, Lupin Limited, Pfizer Inc., Astellas Pharma Inc., Glenmark Pharmaceuticals Ltd., Arbor Pharmaceuticals, LLC and Depomed, Inc. are a few of the promising players in the Europe diabetic neuropathy market.

1. Introduction                                   

            1.1 Market Definition            

            1.2 Scope of the report                     

            1.3 Study Assumptions                      

            1.4 Base Currency, Base Year and Forecast Periods             

2. Research Methodology                             

            2.1 Analysis Design                

            2.2 Research Phases              

                        2.2.1 Secondary Research     

                        2.2.2 Primary Research          

                        2.2.3 Data Modelling 

                        2.2.4 Expert Validation          

            2.3 Study Timeline                 

3. Report Overview                            

            3.1 Executive Summary                     

            3.2 Key Inferences                 

4. Market Dynamics                           

            4.1 Impact Analysis                

                        4.1.1 Drivers  

                        4.1.2 Restraints          

                        4.1.3 Opportunities   

            4.2 Regulatory Environment              

            4.3 Technology Timeline & Recent Trends                

5. Competitor Benchmarking Analysis                                  

            5.1 Key Player Benchmarking            

                        5.1.1 Market share analysis   

                        5.1.2 Products/Service          

                        5.1.3 Regional Presence        

            5.2 Mergers & Acquisition Landscape                       

            5.3 Joint Ventures & Collaborations              

6. Market Segmentation                                

            6.1 Europe Diabetic Neuropathy Market – By Disorder:                   

                        6.1.1 Peripheral Neuropathy 

                        6.1.2 Autonomic Neuropathy

                        6.1.3   Proximal Neuropathy  

                        6.1.4 Focal Neuropathy                     

                        6.1.5 Market Size Estimations & Forecasts (2021-2026)      

                        6.1.6 Y-o-Y Growth Rate Analysis      

                        6.1.7 Market Attractiveness Index    

            6.2 Europe Diabetic Neuropathy Market – By Treatment:                

                        6.2.1   Drugs   

                        6.2.2 Radiotherapy    

                        6.2.3 Market Size Estimations & Forecasts (2021-2026)      

                        6.2.4 Y-o-Y Growth Rate Analysis      

                        6.2.5 Market Attractiveness Index    

            6.3 Europe Diabetic Neuropathy Market – By Distribution Channel:            

                        6.3.1 Hospitals

                        6.3.2    Clinics 

                        6.3.3 Retail Pharmacy

                        6.3.4 Online Pharmacy          

                        6.3.5 Market Size Estimations & Forecasts (2021-2026)      

                        6.3.6 Y-o-Y Growth Rate Analysis      

                        6.3.7 Market Attractiveness Index    

7. Geographical Landscape                                

            7.1. Europe                 

                        7.1.1 By Country        

                                    7.1.1.1 UK

                                    7.1.1.2 France

                                    7.1.1.3 Germany

                                    7.1.1.4 Spain

                                    7.1.1.5 Italy

                                    7.1.1.6 Rest of Europe

                        7.1.2 By Disorder:      

                        7.1.3 By Treatment:   

                        7.1.4 By Distribution Channel:                

8. Key Player Analysis                        

            8.1 Johnson & Johnson (Janssen Europe Services, LLC)                     

                        8.1.1 Business Description    

                        8.1.2 Products/Service          

                        8.1.3 Financials          

                        8.1.4 SWOT Analysis  

                        8.1.5 Recent Developments  

                        8.1.6 Analyst Overview          

            8.2 Boehringer Ingelheim GmbH                   

            8.3 NeuroMetrix, Inc.            

            8.4 Eli Lilly and Company                   

            8.5 GlaxoSmithKline plc                     

            8.6 Lupin Limited                   

            8.7 Pfizer Inc.             

            8.8 Astellas Pharma Inc.                    

            8.9 Glenmark Pharmaceuticals Ltd.              

            8.10 Arbor Pharmaceuticals              

            8.11 LLC and Depomed, Inc.              

9. Market Outlook & Investment Opportunities                               

10. Appendix                          

            List of Tables              

            List of Figures           

  • Regional, and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and also identify the areas that are still untapped. 

  • The segment-level analysis in terms of disorder type, treatment, distribution channel, and region along with market size forecasts and estimations to detect key areas of industry growth in detail.

  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics.

  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis.

  • Study the microenvironment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analyzing the level of competition and business strategy development.

  • A comprehensive list of key market players along with their product portfolio, current strategic interests, essential financial information, legal issues, SWOT analysis, and analyst overview to study and sustain the market environment.

  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies, and recent developments in the market by the major companies

  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis, and main conclusions.

  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations with a strong financial foothold in the market.

  1. Europe Biostimulants Market By Disorder, From 2021 to 2026 ( USD Billion )

  2. Europe Peripheral Neuropathy Market By Region, From 2021 to 2026 ( USD Billion )

  3. Europe  Autonomic Neuropathy Market By Region, From 2021 to 2026 ( USD Billion )

  4. Europe   Proximal Neuropathy Market By Region, From 2021 to 2026 ( USD Billion )

  5. Europe Focal Neuropathy Market By Region, From 2021 to 2026 ( USD Billion )

  6. Europe Biostimulants Market By Treatment, From 2021 to 2026 ( USD Billion )

  7. Europe Biostimulants Market By Distribution Channel, From 2021 to 2026 ( USD Billion )

  8. Europe   Hospitals Market By Region, From 2021 to 2026 ( USD Billion )

  9. Europe Clinics Market By Region, From 2021 to 2026 ( USD Billion )

  10. Europe  Retail Pharmacy Market By Region, From 2021 to 2026 ( USD Billion )

  11. Europe    Online Pharmacy Market By Region, From 2021 to 2026 ( USD Billion )

  12. U.K. Biostimulants Market By Disorder, From 2021 to 2026 ( USD Billion )

  13. U.K. Biostimulants Market By Treatment, From 2021 to 2026 ( USD Billion )

  14. U.K. Biostimulants Market By Distribution Channel, From 2021 to 2026 ( USD Billion )

  15. Germany Biostimulants Market By Disorder, From 2021 to 2026 ( USD Billion )

  16. Germany Biostimulants Market By Treatment, From 2021 to 2026 ( USD Billion )

  17. Germany Biostimulants Market By Distribution Channel, From 2021 to 2026 ( USD Billion )

  18. France Biostimulants Market By Disorder, From 2021 to 2026 ( USD Billion )

  19. France Biostimulants Market By Treatment, From 2021 to 2026 ( USD Billion )

  20. France Biostimulants Market By Distribution Channel, From 2021 to 2026 ( USD Billion )

  21. Italy Biostimulants Market By Disorder, From 2021 to 2026 ( USD Billion )

  22. Italy Biostimulants Market By Treatment, From 2021 to 2026 ( USD Billion )

  23. Italy Biostimulants Market By Distribution Channel, From 2021 to 2026 ( USD Billion )

  24. Spain Biostimulants Market By Disorder, From 2021 to 2026 ( USD Billion )

  25. Spain Biostimulants Market By Treatment, From 2021 to 2026 ( USD Billion )

  26. Spain Biostimulants Market By Distribution Channel, From 2021 to 2026 ( USD Billion )

  27. Europe Diabetic Neuropathy Market By Treatment, From 2021 to 2026 ( USD Million )

  28. Europe    Drugs   Market By Region, From 2021 to 2026 ( USD Million )

  29. U.K. Diabetic Neuropathy Market By Treatment, From 2021 to 2026 ( USD Million )

  30. Germany Diabetic Neuropathy Market By Treatment, From 2021 to 2026 ( USD Million )

  31. France Diabetic Neuropathy Market By Treatment, From 2021 to 2026 ( USD Million )

  32. Italy Diabetic Neuropathy Market By Treatment, From 2021 to 2026 ( USD Million )

  33. Spain Diabetic Neuropathy Market By Treatment, From 2021 to 2026 ( USD Million )

  34. Europe Diabetic Neuropathy Market By Drugs, From 2021 to 2026 ( USD Million )

  35. Europe  Analgesic Market By Region, From 2021 to 2026 ( USD Million )

  36. U.K. Diabetic Neuropathy Market By Drugs, From 2021 to 2026 ( USD Million )

  37. Germany Diabetic Neuropathy Market By Drugs, From 2021 to 2026 ( USD Million )

  38. France Diabetic Neuropathy Market By Drugs, From 2021 to 2026 ( USD Million )

  39. Italy Diabetic Neuropathy Market By Drugs, From 2021 to 2026 ( USD Million )

  40. Spain Diabetic Neuropathy Market By Drugs, From 2021 to 2026 ( USD Million )

  41. Europe Diabetic Neuropathy Market By Analgesic, From 2021 to 2026 ( USD Million )

  42. Europe Topical Market By Region, From 2021 to 2026 ( USD Million )

  43. U.K. Diabetic Neuropathy Market By Analgesic, From 2021 to 2026 ( USD Million )

  44. Germany Diabetic Neuropathy Market By Analgesic, From 2021 to 2026 ( USD Million )

  45. France Diabetic Neuropathy Market By Analgesic, From 2021 to 2026 ( USD Million )

  46. Italy Diabetic Neuropathy Market By Analgesic, From 2021 to 2026 ( USD Million )

  47. Spain Diabetic Neuropathy Market By Analgesic, From 2021 to 2026 ( USD Million )

  48. Europe Diabetic Neuropathy Market By Topical, From 2021 to 2026 ( USD Million )

  49. Europe Capsaicin Market By Region, From 2021 to 2026 ( USD Million )

  50. Europe Others Market By Region, From 2021 to 2026 ( USD Million )

  51. U.K. Diabetic Neuropathy Market By Topical, From 2021 to 2026 ( USD Million )

  52. Germany Diabetic Neuropathy Market By Topical, From 2021 to 2026 ( USD Million )

  53. France Diabetic Neuropathy Market By Topical, From 2021 to 2026 ( USD Million )

  54. Italy Diabetic Neuropathy Market By Topical, From 2021 to 2026 ( USD Million )

  55. Spain Diabetic Neuropathy Market By Topical, From 2021 to 2026 ( USD Million )

  56. Europe Diabetic Neuropathy Market By  Opioid, From 2021 to 2026 ( USD Million )

  57. Europe Morphine Market By Region, From 2021 to 2026 ( USD Million )

  58. Europe Others Market By Region, From 2021 to 2026 ( USD Million )

  59. U.K. Diabetic Neuropathy Market By  Opioid, From 2021 to 2026 ( USD Million )

  60. Germany Diabetic Neuropathy Market By  Opioid, From 2021 to 2026 ( USD Million )

  61. France Diabetic Neuropathy Market By  Opioid, From 2021 to 2026 ( USD Million )

  62. Italy Diabetic Neuropathy Market By  Opioid, From 2021 to 2026 ( USD Million )

  63. Spain Diabetic Neuropathy Market By  Opioid, From 2021 to 2026 ( USD Million )

  64. Europe Diabetic Neuropathy Market By NSAIDs, From 2021 to 2026 ( USD Million )

  65. Europe    Ibuprofen Market By Region, From 2021 to 2026 ( USD Million )

  66. Europe Naproxen Market By Region, From 2021 to 2026 ( USD Million )

  67. Europe Others Market By Region, From 2021 to 2026 ( USD Million )

  68. U.K. Diabetic Neuropathy Market By NSAIDs, From 2021 to 2026 ( USD Million )

  69. Germany Diabetic Neuropathy Market By NSAIDs, From 2021 to 2026 ( USD Million )

  70. France Diabetic Neuropathy Market By NSAIDs, From 2021 to 2026 ( USD Million )

  71. Italy Diabetic Neuropathy Market By NSAIDs, From 2021 to 2026 ( USD Million )

  72. Spain Diabetic Neuropathy Market By NSAIDs, From 2021 to 2026 ( USD Million )

  73. Europe Diabetic Neuropathy Market By Antidepressants, From 2021 to 2026 ( USD Million )

  74. Europe TCAs Market By Region, From 2021 to 2026 ( USD Million )

  75. Europe Naproxen Market By Region, From 2021 to 2026 ( USD Million )

  76. Europe Others Market By Region, From 2021 to 2026 ( USD Million )

  77. U.K. Diabetic Neuropathy Market By Antidepressants, From 2021 to 2026 ( USD Million )

  78. Germany Diabetic Neuropathy Market By Antidepressants, From 2021 to 2026 ( USD Million )

  79. France Diabetic Neuropathy Market By Antidepressants, From 2021 to 2026 ( USD Million )

  80. Italy Diabetic Neuropathy Market By Antidepressants, From 2021 to 2026 ( USD Million )

  81. Spain Diabetic Neuropathy Market By Antidepressants, From 2021 to 2026 ( USD Million )

  82. Europe Diabetic Neuropathy Market By TCAs, From 2021 to 2026 ( USD Million )

  83. Europe Amitriptyline Market By Region, From 2021 to 2026 ( USD Million )

  84. Europe Imipramine Market By Region, From 2021 to 2026 ( USD Million )

  85. Europe   Others Market By Region, From 2021 to 2026 ( USD Million )

  86. U.K. Diabetic Neuropathy Market By TCAs, From 2021 to 2026 ( USD Million )

  87. Germany Diabetic Neuropathy Market By TCAs, From 2021 to 2026 ( USD Million )

  88. France Diabetic Neuropathy Market By TCAs, From 2021 to 2026 ( USD Million )

  89. Italy Diabetic Neuropathy Market By TCAs, From 2021 to 2026 ( USD Million )

  90. Spain Diabetic Neuropathy Market By TCAs, From 2021 to 2026 ( USD Million )

  91. Europe Diabetic Neuropathy Market By  SNRIs, From 2021 to 2026 ( USD Million )

  92. Europe Duloxetine Market By Region, From 2021 to 2026 ( USD Million )

  93. Europe   Others Market By Region, From 2021 to 2026 ( USD Million )

  94. U.K. Diabetic Neuropathy Market By  SNRIs, From 2021 to 2026 ( USD Million )

  95. Germany Diabetic Neuropathy Market By  SNRIs, From 2021 to 2026 ( USD Million )

  96. France Diabetic Neuropathy Market By  SNRIs, From 2021 to 2026 ( USD Million )

  97. Italy Diabetic Neuropathy Market By  SNRIs, From 2021 to 2026 ( USD Million )

  98. Spain Diabetic Neuropathy Market By  SNRIs, From 2021 to 2026 ( USD Million )

  99. Europe Diabetic Neuropathy Market By SSRIs, From 2021 to 2026 ( USD Million )

  100. Europe  Citalopram Market By Region, From 2021 to 2026 ( USD Million )

  101. Europe   Paroxetine Market By Region, From 2021 to 2026 ( USD Million )

  102. Europe  Others Market By Region, From 2021 to 2026 ( USD Million )

  103. U.K. Diabetic Neuropathy Market By SSRIs, From 2021 to 2026 ( USD Million )

  104. Germany Diabetic Neuropathy Market By SSRIs, From 2021 to 2026 ( USD Million )

  105. France Diabetic Neuropathy Market By SSRIs, From 2021 to 2026 ( USD Million )

  106. Italy Diabetic Neuropathy Market By SSRIs, From 2021 to 2026 ( USD Million )

  107. Spain Diabetic Neuropathy Market By SSRIs, From 2021 to 2026 ( USD Million )

  108. Europe Diabetic Neuropathy Market By Anticonvulsant Drugs, From 2021 to 2026 ( USD Million )

  109. Europe Gabapentin Market By Region, From 2021 to 2026 ( USD Million )

  110. Europe Pregabalin Market By Region, From 2021 to 2026 ( USD Million )

  111. Europe Topiramate Market By Region, From 2021 to 2026 ( USD Million )

  112. Europe Others Market By Region, From 2021 to 2026 ( USD Million )

  113. Europe Other Drugs Market By Region, From 2021 to 2026 ( USD Million )

  114. U.K. Diabetic Neuropathy Market By Anticonvulsant Drugs, From 2021 to 2026 ( USD Million )

  115. Germany Diabetic Neuropathy Market By Anticonvulsant Drugs, From 2021 to 2026 ( USD Million )

  116. France Diabetic Neuropathy Market By Anticonvulsant Drugs, From 2021 to 2026 ( USD Million )

  117. Italy Diabetic Neuropathy Market By Anticonvulsant Drugs, From 2021 to 2026 ( USD Million )

  118. Spain Diabetic Neuropathy Market By Anticonvulsant Drugs, From 2021 to 2026 ( USD Million )

  119. Europe Diabetic Neuropathy Market By Radiotherapy, From 2021 to 2026 ( USD Million )

  120. Europe Transcutaneous Electrical Nerve Stimulation (TENS) Market By Region, From 2021 to 2026 ( USD Million )

  121. Europe Others Market By Region, From 2021 to 2026 ( USD Million )

  122. Europe Physiotherapy Market By Region, From 2021 to 2026 ( USD Million )

  123. U.K. Diabetic Neuropathy Market By Radiotherapy, From 2021 to 2026 ( USD Million )

  124. Germany Diabetic Neuropathy Market By Radiotherapy, From 2021 to 2026 ( USD Million )

  125. France Diabetic Neuropathy Market By Radiotherapy, From 2021 to 2026 ( USD Million )

  126. Italy Diabetic Neuropathy Market By Radiotherapy, From 2021 to 2026 ( USD Million )

  127. Spain Diabetic Neuropathy Market By Radiotherapy, From 2021 to 2026 ( USD Million )

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample